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Mutations in the CHEK2 gene confer an
approximately two-fold increase in the risk of cancer
in many organs including the breast, colon, kidney,
prostate and thyroid. In addition, we have recently
identified a positive association of similar magnitude
between a CHEK2 mutation and bladder cancer,
endometrial cancer and low-grade ovarian cancer
(unpublished data). Surveillance is available for most
CHEK2-associated cancers. CHEK2 is not a high-risk
gene, but it is associated with multi-cancer susceptibility,
and founder alleles in CHEK2 are common in Poland
(5.5% of the general population); therefore CHEK2 is
responsible for development of more cases of cancer
in Poland than founder mutations known to date in
high-risk genes (including those in BRCA1, MSH2 and
MLH1).
In 2005 in cooperation with the Center of Medical
Diagnosis and Hematology (BIOS) and the journal
Wprost we performed population screening of CHEK2
mutations in Warsaw. This study was started by
publication of an article describing the association of
the CHEK2 gene and multi-site cancer predisposition.
Readers of Wprost journal were invited for genetic
consultation and CHEK2 gene testing. Patients who
responded to the invitation were interviewed in the
BIOS centre. During the interview the goals of the study
were explained, informed consent was obtained, a first
session of genetic counselling was given and a blood
sample was obtained for DNA analysis. A detailed
family history of cancer was taken from all patients (first-
and second-degree relatives included). 
During a period of 6 months, 3,826 individuals
participated in this study. We identified: 192 carriers
of a CHEK2 mutation, 240 families with hereditary
susceptibility to breast and/or ovarian cancer, 62
families with familial colorectal cancer (including
HNPCC). In addition, BRAC1 testing was performed
in all individuals with a positive family history of breast
or ovarian cancer. Twenty-one BRCA1 mutation carriers
were identified. CHEK2 and BRCA1 mutation status
was investigated using two independent blood samples.
Then, all patients were invited for a second session and
final genetic counselling was given. Appropriate
surveillance was recommended for patients with familial
cancer aggregations, as well as for BRAC1 and CHEK2
mutation carriers. We believe that this action
broadened the knowledge about the role of genetic
counselling and DNA testing in cancer prevention in
Poland. It has also shown that many people in our
population need such counselling and surveillance.
We believe that this action will help reduce cancer
morbidity and mortality in Poland.
